BioSpace News Archive

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease in concert with Virgina Commonwealth University (VCU) and Barrow Neurological Institute have received a grant from the Department of Defense.

Seelos Therapeutics, Inc. today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.

Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC).

NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that its Chief Executive Officer, Alex Zwyer, has issued the following letter to shareholders:

Neogen Corporation (NASDAQ: NEOG) will issue its second-quarter earnings release before the opening of the market on Thursday, January 5, 2023.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received an interim response from the U.S. Food and Drug Administration (FDA) to its Formal Dispute Resolution Request regarding the Complete Response Letter received in March 2022 for vadadustat.

The global immune checkpoint inhibitors market size accounted for USD 37.31 billion in 2022 and is expected to attain around USD 148.1 billion by 2030 with a noteworthy CAGR of 18.81% from 2022 to 2030.

Today, the U.S. Food and Drug Administration approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.

AB Science SA announced that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank.

Immunis, Inc., a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its first-in-human injection of IMM01-STEM for its STEM-MYO Phase 1/2a clinical trial.